TY  - BOOK
AU  - Horisberger,Bruno
AU  - Dinkel,Rolf
TI  - The perception and management of drug safety risks
T2  - Health Systems Research
SN  - 3540505342
U1  - 615.19 
PY  - 1989///
CY  - Berlin, Heidelberg, New York
PB  - Springer Berlin Heidelberg
KW  - Health risk assessment
KW  - Εκτίμηση κινδύνου για την υγεία
KW  - Φαρμακολογία
KW  - Pharmacology
N1  - Περιέχει παράρτημα με τα Βιογραφικά των συγγραφέων, γλωσσαριο και πίνακες; Βιβλιογραφία : σ.191-201; Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment
ER  -